Join Us

We are 219,696 members in 84 forums discussing 161,626 topics.

Help with Abbreviations

Topic: Breaking Research News from sources other than Breastcancer.org

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Nov 21, 2017 12:31AM - edited Nov 21, 2017 12:35AM by Lumpie

Lumpie wrote:

I watch for research news on breast cancer, treatments, etc., and frequently see interesting articles. There is a topic on BCO called "Breaking Research News from Breastcancer.org." One of the moderators suggested that another topic might be appropriate for posting links and synopses of reports on research found elsewhere. So here it is! Please post links to reports on research form reliable sources. Thanks for sharing!

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Page 85 of 85 (2,535 results)

Posts 2521 - 2535 (2,535 total)

Log in to post a reply

Jan 13, 2021 10:44AM HomeMom wrote:

LilyisHere.. This is the study my MO told me about. I am currently in year 7 with the end being this December. She and I agreed to extending two years instead of 5 with us discussing it at the end of 7. Reading your link I fall into the high ER and low grade tumors giving me an "excellent prognosis" which would explain the positive attitudes of all my doctors. I'm debating whether to continue to year 10. I wonder if there is any place you can see just how toxic the AI's are. That would help in my decision. Has anyone seen this ?

Dx 3/31/2014, IDC, 2cm, Stage IIB, Grade 1, 3/29 nodes, ER+/PR+, HER2- Surgery 4/15/2014 Lumpectomy: Left Surgery 5/6/2014 Lymph node removal: Left, Underarm/Axillary; Mastectomy: Left; Reconstruction (left): Tissue expander placement Chemotherapy 5/30/2014 AC Chemotherapy 7/25/2014 Taxol (paclitaxel) Radiation Therapy 10/16/2014 Hormonal Therapy 12/15/2014 Arimidex (anastrozole)
Log in to post a reply

Jan 13, 2021 11:26AM - edited Jan 13, 2021 11:27AM by Lumpie

HHS Tells States to Open Vaccine Access to Vulnerable Adults — Given healthy vaccine supply, second doses will no longer be withheld, says HHS Secretary

January 12, 2021

...Azar said it was time to broaden the scope of eligible recipients, and to expand the number and type of delivery sites. He outlined the administration's plans to carry out the following actions:

  • Direct states to expand the populations eligible to receive COVID vaccine doses to those ages ≥65 and those ages <65 with comorbidities as validated by medical documentation (the latter will be determined by state governors)
Azar outlined the reallocation of vaccine doses to those states that are most effective in administering them, based on self-report, and to those states with the greatest numbers of adults who are over age 65. In 2 weeks, allocations will no longer be determined simply by a state's population but by the percentage of vaccines administered compared to the allocation a state received, he explained.

https://www.medpagetoday.com/infectiousdisease/cov...


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Jan 13, 2021 11:42AM BevJen wrote:

Lumpie,

Thanks for posting. I just wrote to our governor and our county executive about this (I live in Maryland) -- so far they are sticking to their guns about the original distribution schedule. Hope this changes.

Microwave Ablations of the Liver: 7/2019; 10/2020; 12/2020 Dx 11/2003, ILC, Left, Stage IIIC, 13/18 nodes, ER+/PR+, HER2- Dx 6/2006, ILC, Stage IV, metastasized to other, ER+, HER2- Dx 5/2019, ILC, Stage IV, metastasized to liver, ER+/PR+, HER2- Surgery 7/4/2019 Targeted Therapy 7/31/2019 Ibrance (palbociclib) Immunotherapy Radiation Therapy Surgery Lymph node removal: Left, Sentinel; Mastectomy: Left, Right; Reconstruction (left): Pedicled TRAM flap; Reconstruction (right): Pedicled TRAM flap Chemotherapy TAC Hormonal Therapy Faslodex (fulvestrant) Hormonal Therapy Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone) Surgery Lymph node removal; Mastectomy; Reconstruction (left): Pedicled TRAM flap; Reconstruction (right): Pedicled TRAM flap Hormonal Therapy Femara (letrozole)
Log in to post a reply

Jan 13, 2021 01:53PM - edited Jan 13, 2021 01:53PM by Lumpie

After 48 Years, NCI Aims to Track Breast Cancer Recurrences
Change to SEER Eventually Planned

January 08, 2021

Patients with breast cancer want accurate information on the risk of their cancer recurring once they have completed treatment.

But those statistics have not been available from a robust population-based source.

Now, there is hope that they will ― at last ― be collected.

A new pilot project at the National Cancer Institute (NCI) is setting out to collect that information, although the researchers say it is a "long-term goal" that will take a few years.

But it has already been a long time coming. The mother lode of all US cancer data, the NCI's Surveillance, Epidemiology, and End Results (SEER) Program, started collecting cancer data in 1973.

{The SEER} database has never included information on cancer recurrence.

The NCI now has a "long-term goal" to implement additional "data elements" into SEER that will allow calculation of breast cancer recurrences...

Breast cancer advocates have long been calling for SEER to count recurrence, including metastatic recurrence.

https://www.medscape.com/viewarticle/943796?fbclid...

{Free access to reporting. Registration may be required.}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Jan 13, 2021 05:27PM BlueGirlRedState wrote:

Lumpie - thank you for posting NCI starting to track/examine recurrence probability. Increadible that this is not being done. It seems like it could really influence treatment. I've been told that even if tumor from time 1 to time X were compared, cancer mutates so much, that it might be difficult to know if it is recurrence, a new cancer, or maybe even if the original cancer was not irradicated the first time. I wonder to if monitoring would be more rigorous and able to catch cancer recurrence/new cancer sooner.

Log in to post a reply

Jan 13, 2021 10:43PM AlabamaDee wrote:

Have you seen this? A clinical trial with your own MO.

Thanks Christine Hodgdon at https://thestormriders.org/ for posting this on Twitter

If you have the SF3B1 mutation, you may be eligible for the PRISMM trial which allows you to receive immunotherapy at your local cancer clinic without ever having to travel! https://clinicaltrials.gov/ct2/show/NCT04447651


Dee

Primary neuroendocrine breast cancer, on SERD trial ARV-471, failed Pfizer’s CDK 2/4/6 trial after 8 weeks Dx 5/23/2013, Right, 1cm, Stage IIB, Grade 2, 1/22 nodes, ER+/PR+, HER2- (FISH) Chemotherapy 7/29/2013 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 4/2019, Stage IV, metastasized to liver, ER+/PR+, HER2- Targeted Therapy 10/8/2020 Chemotherapy Doxil (doxorubicin) Targeted Therapy Afinitor (everolimus) Hormonal Therapy Faslodex (fulvestrant) Hormonal Therapy Arimidex (anastrozole), Aromasin (exemestane), Fareston (toremifene), Femara (letrozole) Hormonal Therapy Faslodex (fulvestrant) Targeted Therapy Verzenio Chemotherapy Xeloda (capecitabine)
Log in to post a reply

Jan 15, 2021 08:37PM 2019whatayear wrote:

from JAMA an editorial on reducing recurrence in early TN

https://jamanetwork.com/journals/jama/fullarticle/2774294?guestAccessKey=b7407608-cd02-4749-8b70-d452dd7f4611&utm_source=twitter&utm_medium=social_jamaonc&utm_term=4398671864&utm_campaign=partnership&linkId=108976106


5/6/2019 IDC 2cm, micromet 1/9 nodes, BRCA2+, ER+, PR+, HER- BMX 6/2019, A/C & Taxol 2019, Radiation, BSO - preventative 2/2020, Letrozole 3/1/2020
Log in to post a reply

Jan 20, 2021 10:30AM Lumpie wrote:

Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Cancers
The Lancet Oncology, January 07, 2021
  • The authors of this prospective National Health Service registry–based observational study evaluated the outcomes of 1422 patients with solid cancer extracranial oligometastatic disease treated with stereotactic ablative body radiotherapy. The 1- and 2-year overall survival rates were 92% and 79%, respectively. Grade 3/4 toxicity was rare.
  • These real-world findings support both earlier trial data and this therapeutic approach in the selected patient population.
https://www.practiceupdate.com/C/111868/56?elsca1=...
https://www.thelancet.com/journals/lanonc/article/...(20)30537-4/fulltext
DOI:https://doi.org/10.1016/S1470-2045(20)30537-4
{Free access to reporting and abstract. Full article requires fee or subscription.}
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Jan 21, 2021 03:49PM mysticalcity wrote:

Oncotype DX Misses on Breast Cancer Risk in Black Women — Accuracy of 21-gene recurrence score worse compared with white women

https://www.medpagetoday.com/hematologyoncology/breastcancer/90813

Dx 3/22/2018, ILC/IDC, Left, 2cm, Stage IIA, Grade 2, ER+/PR-, HER2- Hormonal Therapy 5/31/2018 Arimidex (anastrozole) Surgery 6/26/2019 Cryotherapy: Left Radiation Therapy
Log in to post a reply

Jan 22, 2021 10:59PM Lumpie wrote:

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer -- A Phase 3 Randomized Clinical Trial

JAMA Oncol. Published online January 22, 2021

Results A total of 536 patients were randomized to receive margetuximab (n = 266) or trastuzumab (n = 270). The median age was 56 (27-86) years; 266 (100%) women were in the margetuximab group, while 267 (98.9%) women were in the trastuzumab group. Groups were balanced. All but 1 patient had received prior pertuzumab, and 489 (91.2%) had received prior ado-trastuzumab emtansine. Margetuximabhttps://jamanetwork.com/journals/jamaoncology/full...improved primary PFS over trastuzumab with 24% relative risk reduction (hazard ratio [HR], 0.76; 95% CI, 0.59-0.98; P = .03; median, 5.8 [95% CI, 5.5-7.0] months vs 4.9 [95% CI, 4.2-5.6] months; October 10, 2018). After the second planned interim analysis of 270 deaths, median OS was 21.6 months with margetuximab vs 19.8 months with trastuzumab (HR, 0.89; 95% CI, 0.69-1.13; P = .33; September 10, 2019), and investigator-assessed PFS showed 29% relative risk reduction favoring margetuximab (HR, 0.71; 95% CI, 0.58-0.86; P < .001; median, 5.7 vs 4.4 months; September 10, 2019). Margetuximab improved objective response rate over trastuzumab: 22% vs 16% (P = .06; October 10, 2018), and 25% vs 14% (P < .001; September 10, 2019). Incidence of infusion-related reactions, mostly in cycle 1, was higher with margetuximab (35 [13.3%] vs 9 [3.4%]); otherwise, safety was comparable.

Conclusions and Relevance In this phase 3 randomized clinical trial, margetuximab plus chemotherapy had acceptable safety and a statistically significant improvement in PFS compared with trastuzumab plus chemotherapy in ERBB2-positive ABC after progression on 2 or more prior anti-ERBB2 therapies. Final OS analysis is expected in 2021.

Trial Registration ClinicalTrials.gov Identifier: NCT02492711

https://jamanetwork.com/journals/jamaoncology/full...

doi:10.1001/jamaoncol.2020.7932

{appears to be open access}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Jan 23, 2021 05:39PM mysticalcity wrote:

Aspirin linked to better survival rates for bladder and breast cancer https://www1.racgp.org.au/newsgp/clinical/aspirin-associated-with-better-survival-rates-for

Dx 3/22/2018, ILC/IDC, Left, 2cm, Stage IIA, Grade 2, ER+/PR-, HER2- Hormonal Therapy 5/31/2018 Arimidex (anastrozole) Surgery 6/26/2019 Cryotherapy: Left Radiation Therapy
Log in to post a reply

Jan 25, 2021 06:40PM moth wrote:

Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer https://ascopost.com/issues/january-25-2021/unexpe...

key points:

phase 2 trial reporting

pts were pre-treated

trilaciclib is an IV cdk4/6 inhibitor

was given w. gemcitabine plus carboplatin

"The outcome in the PD-L1–positive subset (57.6% of those tested) was notable, with overall survival of 32.7 months vs 10.5 (hazard ratio = 0.34; P = .004)."


"We plan to initiate a registrational trial for trilaciclib in mTNBC in 2021, with overall survival as the primary outcome measure"

More from the manufacturer here: https://www.g1therapeutics.com/pipeline/trilacicli...





Initial dx at 50. Seriously???? “Sometimes the future changes quickly and completely and we’re left with only the choice of what to do next." blog: nevertellmetheodds2017.tumblr.... Dx 12/2017, IDC, Left, 1cm, Stage IA, Grade 3, 0/5 nodes, ER-/PR-, HER2- (IHC) Surgery 12/12/2017 Lumpectomy: Left; Lymph node removal: Sentinel Chemotherapy 2/14/2018 AC + T (Taxol) Radiation Therapy 8/13/2018 Whole-breast: Breast Dx 2/2020, IDC, Stage IV, metastasized to liver/lungs, Grade 3, ER-/PR-, HER2- Chemotherapy 3/18/2020 Taxol (paclitaxel) Immunotherapy 3/19/2020 Tecentriq (atezolizumab) Chemotherapy 11/26/2020 Abraxane (albumin-bound or nab-paclitaxel) Dx 12/10/2020, IDC, Right, Stage IV, metastasized to lungs, Grade 3, ER+/PR-, HER2- (IHC) Radiation Therapy 12/10/2020 External Hormonal Therapy 12/16/2020 Femara (letrozole)
Log in to post a reply

Jan 25, 2021 07:10PM Lumpie wrote:

Large studies estimate breast cancer risk linked to specific genes

January 20, 2021

Two large studies published in the New England Journal of Medicine found pathogenic variants in BRCA1 or BRCA2 genes raise the carrier's risk for breast cancer by nearly eightfold or more than fivefold, respectively, and protein-truncating variants in BRCA1 was linked to a tenfold higher risk. Moderate breast cancer risk was also associated with mutations in PALB2, ARD1, RAD51C, RAD51D, ATM and CHEK2 genes, and specific genes were linked to risks for specific types of breast cancer.

CONCLUSIONS

This study provides estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known breast cancer–predisposition genes in the U.S. population. These estimates can inform cancer testing and screening and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes. (Funded by the National Institutes of Health and the Breast Cancer Research Foundation.)

Reporting courtesy of AANP SmartBrief

https://www.medpagetoday.com/hematologyoncology/br...

https://apnews.com/article/us-news-genetics-cancer...

https://www.nejm.org/doi/full/10.1056/nejmoa200593...

DOI: 10.1056/NEJMoa2005936

{Coverage free of charge but may require registration; abstract w/o charge. Access to full article in NEJM requires fee or subscription.}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

11 hours ago - edited 11 hours ago by Bakerstreet

Breast cancer: Androgen therapy shows promise in preliminary study

Scientists have embarked on renewed investigations into androgen therapy — a former breast cancer treatment. Recent research in mice shows that it may help block tumor growth.

....

Androgen therapy was practiced during the first half of the 20th century, according to a paper published in the American Journal of Cancer Research. Doctors stopped using it for breast cancer, though, when scientists determined that "Androgens can be converted to estrogens."

This led researchers to believe that androgen therapy could do more harm than good, since an increase in estrogen is linked with breast cancer.

However, in a recent study published in Nature Medicine, researchers decided to take another look at this use of androgens. The team discovered that this hormone may, after all, contribute to fighting breast cancer.

The researchers — many from the University of Adelaide, in Australia — studied the effect of androgen receptor-activating drugs on cell cultures and mouse models of breast cancer. In these mice, the scientists had implanted tumors extracted from patients with breast cancer.

They found that activating androgen receptors had a "potent" suppressive effect on different kinds of breast cancer tumors, even those that had been resistent to "traditional" treaments with estrogen receptor inhibitors and CDK4/6 inhibitors.

Log in to post a reply

7 hours ago Lumpie wrote:

Signatures of Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer
  • The authors of this retrospective analysis performed whole-exome sequencing on retreatment tumor samples in patients with previously treated, primary invasive HER2 negative breast cancer to evaluate the mutational signals which may be predictive of tumor response and resistance to neoadjuvant chemotherapy. Different breast cancer subgroups could be identified by differences in homologous recombination deficiency (HRD)–associated APOBEC-related mutations. For HR-positive tumors, the mutational signal S13 showed a strong correlation with an increased pathological complete response (pCR) rate while the S3 signal for HRD was borderline significant. Tumors with a high S13 signal had a median pCR of 22% versus 4% in tumors with low S13 levels. HR-positive tumors were noted to have signatures S3 and S4 associated with reduced disease-free survival, but these were nonsignificant in multivariate analysis. In contrast, HR-negative tumors had no mutational signatures associated with pCR.
  • Whole-exome sequencing revealed that the clinical behavior of particular tumor types could be predicted by the mutational signatures. This requires validation and confirmation of relevant mutational signatures but may help to identify tumor types more rapidly responsive to neoadjuvant chemotherapy to inform treatment decisions.
https://www.practiceupdate.com/C/111995/56?elsca1=...
https://www.annalsofoncology.org/action/showPdf?pi...
DOI:https://doi.org/10.1016/j.annonc.2020.12.016
{Free access to reporting and abstract. Full article requires subscription or fee.}
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast

Page 85 of 85 (2,535 results)